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ABSTRAK  
 
Pengenalan 
Pembedahan dianggap sebagai modaliti rawatan utama dalam kebanyakan kes kanser 
kolorektal dan pencapaian pembedahan yang selamat dari segi onkologi telah terbukti dapat 
dilakukan secara pendekatan laparoskopi. Keraguan dalam mengamalkan kaedah ini mungkin 
disebabkan oleh lengkung graf pembelajaran yang curam dan kebimbangan keselamatan dari 
segi onkologi. Salah satu kajian yang biasa dilakukan untuk hasil onkologi adalah kadar kes 
kanser kolorektal berulang yang berlaku paling kerap dalam tempoh 2 tahun pertama selepas 
pembedahan. Untuk kemajuan ke arah pembedahan secara laparoskopi sebagai rutin, kajian 
ini bertujuan untuk membandingkan kadar kes ulangan 2 tahun bagi kes-kes kanser kolorektal 
yang di bedah secara laparoskopi dengan ulasan antarabangsa dan untuk menggambarkan 
faktor klinikopatologi yang boleh menyumbang kepada risiko berulang.  
 
Methodologi 
Ini adalah kajian pemerhatian retrospektif terhadap pesakit-pesakit yang telah disahkan 
menghidap kanser kolorektal dan telah menjalani pembedahan kolekomi laparoskopik secara 
elektif di HUSM dari Januari 2007 hingga Disember 2014. Semua pesakit yang mendapat 
rawatan susulan untuk minimum 24 bulan dan mempunyai rekod klinikal di HUSM 
dimasukkan dalam kajian ini manakala pesakit yang mempunyai pathologi lain pada masa 
yang sama dikeluarkandaripada kajian ini. Data kliniko-pathologi dan butiran rawatan 
susulan selama 2 tahun selepas pembedahan dikaji. Data dikumpulkan dalam proforma 
berstruktur dan analisis survival dilakukan menggunakan ―Cox regression formula‖. Hasil 
pengumpulan data dan analisis kemudiannya dibandingkan dengan hasil kajian yang 
dilakukan di peringkat antarabangsa. 
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Keputusan 
Dari tempoh Januari 2007 sehingga Disember 2014, sejumlah 53 pesakit menjalani 
pembedahan kolektomi laparoskopi secara elektif bagi rawatan kanser kolorectal. Sejumlah 
13 pesakit dikecualikan, analisis dilakukan ke atas 40 pesakit. Umur purata ketika 
pembedahan ialah 61.5 tahun. 55% daripada pesakit adalah lelaki dan 45% adalah wanita dan 
90% daripada pesakit adalah Melayu manakala 10% lagi adalah Cina. Kebanyakan kes 
adalah kanser pada usus kiri (95%), 42.5% daripada mereka adalah kes kanser anorektal atau 
rektal sahaja. Terdapat 4 pesakit (10%) dengan penyakit pada tahap I, 14 pesakit (35%) pada 
tahap II, 12 pesakit (30%) pada tahap III dan 10 pesakit (25%) pada tahap IV. Daripada 40 
pesakit tersebut, terdapat 5 kes berulang dalam masa 2 tahun selepas pembedahan 
menjadikan kadar berulang sebanyak 12.5%. Masa purata untuk penyakit berulang adalah 
21.2 bulan dengan pengulangan terawal terjadi pada 15 bulan selepas pembedahan. 
Berdasarkan formula ―simple cox regression‖, mereka yang mempunyai serum 
―carcinoembryonic Antigen‖ (CEA) yang lebih tinggi selepas pembedahan mempunyai risiko 
yang lebih untuk mendapat karsinoma kolorektal yang berulang (HR=1.05, 95% CI: 1.00, 
1.10, nilai P =0.04). Faktor-faktor lain seperti pesakit yang mempunyai satu atau lebih 
komorbiditi, tahap T, N atau M akhir, tahap kumpulan akhir, limfovaskular atau perineural 
invasi dan terdapat terapi tambahan sebelum ataupun selepas pembedahan secara statistiknya, 
tidak signifikan (nilai P ≥ 0.05) dalam menambah risiko untuk ulangan dalam masa 2 tahun. 
 
Kesimpulan 
Kadar kes berulang bagi kes-kes kanser kolorektal yang dibedah secara laparoskopik di 
HUSM adalah setaraf dengan kadar pada peringkat antarabangsa. Nilai serum CEA semasa 
rawatan susulan pertama yang lebih tinggi, mencadangkan kemungkinan risiko lebih tinggi 
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untuk berulang. Oleh itu, ia mampu menjadi satu indikator awal untuk kes berulang. 
Walaupun fackor-faktor lain seperti tahap penyakit, status nodal dan bilangan nodus limpa 
yang dikeluarkan mungkin mempunyai kaitan, tetapi tiada yang signifikan dari segi statistik. 
Sejajar dengan kemajuan tren ke arah pembedahan invasif minima, usaha yang berterusan 
dari segi audit dan kajian diperlukan bagi menambahbaik mutu hasil pembedahan. 
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ABSTRACT 
 
Introduction 
Surgical resection is considered the primary treatment modality in most cases of colorectal 
carcinoma and achievement of an oncologically-sound resection has been shown to be 
possible by laparoscopic approach. The hesitation in adopting this method may be because of 
the steep learning curve and concerns of oncologic safety. A commonly studied measure of 
oncologic outcome is the recurrence rate which, in colorectal cancer occurs most commonly 
within the first 2 years post resection. This study aims to compare the 2-year recurrence rates 
of colorectal cancer cases resected laparoscopically to that reported internationally and to 
describe clinicopathologic factors that may contribute to the risk of recurrence. 
 
Methods 
This is a retrospective observational study of the patients diagnosed with colorectal cancer 
who underwent elective laparoscopic colectomy in HUSM from January 2007 to December 
2014. All such patients who had a minimum 24-month follow-up and traceable records were 
included in the study whilst those with concurrent pathologies were excluded. Patients‘ 
clinicopathological data and follow-up details for 2 years post-surgery was studied. Data was 
collected in a structured proforma and the survival analysis of which was done using Cox 
regression formula. The results of data collection and analysis were then compared to results 
of studies conducted internationally.  
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Results 
From the period of January 2007 to December 2014, a total of 53 patients underwent elective 
laparoscopic colectomy for colorectal cancer. A total of thirteen patients were excluded thus, 
data analysis was performed for 40 patients. The mean age at surgery was 61.5 years. 55% of 
patients were male whilst 45% were female and 90% of the patients were Malay whilst the 
remaining 10% were Chinese. Majority of the cases were left sided cancers (95%), 42.5% of 
whom were cases of anorectal or rectal cancers. There were 4 (10%) patients with Stage I 
disease, 14 (35%) patients with Stage II disease, 12 (30%) patients with Stage III disease and 
10 (25%) patients with Stage IV disease. Five patients had recurrence within 2 years post-
surgery resulting in a recurrence rate of 12.5% which was within the range of recurrence rates 
of 3 to 15.6% reported internationally. The mean time to disease recurrence was 21.2 months 
with the earliest recurrence occurring at 15 months post-surgery. Based on the simple cox 
regression formula, those with higher post-operative serum CEA have a higher risk of 
recurrence of colorectal carcinoma (HR=1.05, 95%CI: 1.00, 1.10, P value=0.04). Other 
factors such as presence of one or more comorbidities, final T, N or M stage, final group 
stage, tumour margin clearance, presence of lymphovascular or perineural invasion and 
presence of neoadjuvant or adjuvant therapy were not significant (P value>0.05) in an 
increased risk of recurrence within 2 years post-surgery.  
 
Conclusion 
The recurrence rate for laparoscopically resected colorectal cancers done in HUSM is 
comparable to international standards. A higher post-operative serum CEA suggests a higher 
risk for recurrence and thus, may be used as an early indicator for recurrence. Although other 
factors such as disease stage, nodal status and lymph node harvest appeared to have a 
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possible association, none were statistically significant. As we catch on with the rising trend 
of minimally-invasive surgery, continued effort towards self-audit and research is warranted 
to improve our surgical outcomes.
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A. INTRODUCTION 
 
i. Literature review 
 
Surgical resection is considered the primary treatment modality in most cases of 
colorectal carcinoma and curative results can be achieved with appropriate adjuvant therapy. 
Keeping in mind the need for an oncologically-sound resection, the surgeon‘s goals would 
include complete excision of the primary tumour, its major vascular pedicle and lymphatic 
drainage basin of the affected colonic segment. (Wasserberg, 2010) Resection can be done 
either by the contemporary laparoscopic or the conventional open approach. 
In the past decades, laparoscopic colectomy for resection of colorectal malignancies has 
been gaining its popularity though at a slow pace. There have been concerns regarding the 
oncologic outcomes of laparoscopically-resected colorectal malignancies as previously 
highlighted in a report of the forth port-site recurrence post laparoscopic colectomy by 
Cirrocco et al. The latter had even concluded that ―abdominal wall cancer recurrence is 
enhanced by the laparoscopic approach to colorectal cancer‖ and shunned the method, 
suggesting that it only be performed in controlled, clinical studies. (Cirocco, Schwartzman 
and Golub, 1994) 
Thus, laparoscopic colectomy for malignancy remained infrequently performed until a 
number of large, prospective, randomized controlled studies such as the Barcelona, MRC-
CLASSIC, COLOR and COST trials compared open to laparoscopic approach and addressed 
the major concern of oncologic safety.  
The Barcelona trial involved 219 randomly selected patients who fit the inclusion criteria 
of a single tumour at least 15cm from the anal verge and studied their cancer-related survival 
over a 5-year period. They found that laparoscopic resection was superior in stage III colon 
cancer. The parameters that showed superior outcome in the laparoscopic colectomy group 
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were morbidity, hospital stay, tumour recurrence and cancer-related survival. (Lacy et al., 
2002) 
A 48-institution-strong multicentre randomized control study performed by the COST 
study group recruited a sizeable sample of 1735 patients with the primary study objective of 
―time to tumour recurrence‖. What they found was that the recurrent rates in laparoscopic-
assisted colectomy and open colectomy were comparable and thus, an acceptable alternative 
to open surgery.(The Clinical Outcomes of Surgical Therapy Study Group, 2004)
 
Based on 
this data, it was also discovered that laparoscopic colectomy done for curable colon was not 
inferior to open surgery with recurrence rates that were similar between both groups. Other 
oncologic outcomes such as disease-free 5-year survival and overall 5-year survival were also 
found to be similar between the open and laparoscopic groups.(Fleshman et al., 2007) 
Consolidating all the above trials in a meta-analysis was a refreshing effort by the 
Transatlantic Laparoscopically Assisted vs Open Colectomy Trials Study Group who aimed 
to enhance the surgeon‘s ability to choose between laparoscopic or open techniques. They 
concluded that laparoscopic colectomy was oncologically safe.
 
(Bonjer et al., 2007) 
Evidently, as noted by the COLOR study group in 2005, a higher volume of cases has 
been shown to have a positive impact on the short term results of laparoscopic colectomy for 
colorectal carcinoma.(Veldkamp et al., 2005) A self-audit done by the Royal Brisbane 
Hospital in Australia showed that amongst the 181 patients who underwent laparoscopic 
resection for colorectal cancer in their hospital,  the procedure produces acceptable 
intermediate to long-term oncologic outcomes and a low long-term complication rate in 
selected patients.(Lumley et al., 2002) For centers about to embark on or new to the 
laparoscopic colectomy as the primary choice of resection, it may be reassuring to know that 
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in a small-volume setting this technique is safe when performed by the general surgeon with 
advanced laparoscopic skills. (Gandy & Berney, 2014) 
Perhaps owing to the steep learning curve and advanced skills required, not many 
surgeons choose to perform laparoscopic resection in Malaysia. This is reflected in the 
Malaysian local census which found that only about 16% of colorectal carcinoma cases 
underwent laparoscopic resection. To date, there is no existing local data on the oncologic 
outcomes of laparoscopically resected colorectal cancers. With the knowledge that majority 
of cases recur within the first 2 years of resection,(Scholefield et al., 2002) it seems logical to 
look into the recurrence rates within this period when evaluating our progress at the early 
stage of our learning curve. Thus, this study aims to provide better knowledge of the short to 
midterm oncologic outcome of laparoscopic colectomy in HUSM and describe the factors 
that may contribute to higher risk for recurrence. 
 
ii. Rationale for study 
 
In Hospital Universiti Sains Malaysia (HUSM), one of the major teaching hospitals in 
Malaysia, laparoscopic surgeries have been in place since the mid-1990s but laparoscopic 
colectomy for colorectal carcinoma has been used as the choice technique only recently.   
Currently, there is no existing data on our progress in terms of the oncologic outcome of 
the cases of laparoscopically resected colorectal cancers. Possibly, more information at hand 
may serve as an encouragement to choose the laparoscopic approach to resection of 
colorectal carcinomas. And, perhaps, it can help us to identify any short-comings in our 
perioperative management and post-operative follow-up. 
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 This study aims to:  
 To determine the proportion cases of with recurrence within 2 years post-surgery 
amongst those who had undergone laparoscopic resection of colorectal 
carcinomas in HUSM. 
 To describe factors that may contribute to the risk of recurrence, specifically:  
- Patient factors (age and gender, co-morbid diseases) 
- Disease factors (pre- and post-operative staging, tumour site and serum 
Carcinoembyronic Antigen (CEA) levels) 
- Histopathologic factors (TNM stage, histologic type and differentiation of 
the tumour, involvement of resection margin)  
- Presence of neoadjuvant or adjuvant therapy  
- Time lapse between surgery and commencement of neoadjuvant and/or 
adjuvant therapy 
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B. STUDY PROTOCOL 
 
i. Document submitted for ethical approval 
 
Chairperson 
Jawatankuasa Etika Penyelidikan (Manusia) USM 
Health Campus 
Universiti Sains Malaysia 
16150 Kubang Kerian, Kelantan 
 
Dear Sir/ Madam,  
RE: Revised Study Protocol for Protocol Title: A Review of the 2-Year Recurrence 
Rates in Laparoscopically Resected Colorectal Malignancies in Hospital Universiti 
Sains Malaysia, JEPeM Code: USM/JEPeM/17010059 
 
Herewith is the revised study protocol as per the recommendations of the ethical committee 
board for your perusal. The modifications have been underlined and bolded as per 
instructions and the following is the list of modifications made:  
1) Objectives: Rephrased general objective to ―To determine‖ and specific objective to 
―To describe‖ on page 4 of this document. 
2) Additional information regarding recurrence rates in pre-existing literature with 
citation on pages 2 and 6 of this document. 
3) Modifications and correction of methodology particularly the sampling design, 
inclusion and exclusion criteria, statistical and data analysis plan on pages 7, 8 and 9 
of this document. 
4) Removal of ―Name‖ section in Data collection form on page 13 of this document.  
Your consideration to accept the ethics application for this study protocol is much 
appreciated.  
Thank you for your time.  
 
Regards,  
Dr Khairun Nisa‘ Binti Mohamed 
Department of Surgery 
School of Medical Sciences 
Health Campus,  
Universiti Sains Malaysia 
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Introduction 
 
Colorectal cancer is any malignant growth that develops within any part of the large bowel 
(from caecum to the anorectal junction). It is one of the commonest cancers globally; and in 
Malaysia, it is the second commonest with an incidence rate of 21.3 per 100,000 
populations.
(1)
 Locally, majority of colorectal cancer cases are diagnosed at stage III or IV 
and they account for 63.5% of newly diagnosed cases.
(2)
  
Surgical resection is considered the primary treatment modality in most cases and curative 
results can be achieved with appropriate adjuvant therapy. Keeping in mind the need for an 
oncologically-sound resection, the surgeon‘s goals would include complete excision of the 
primary tumour, its major vascular pedicle and lymphatic drainage basin of the affected 
colonic segment. Resection can be done either by the ―contemporary‖ laparoscopic or the 
―conventional‖ open approach.  
Post primary curative resection, colorectal cancer has a reported incidence of recurrence 
between 10-30% with the highest rate of recurrence for stage 3 disease. 
(3,4,5,6)
 Majority of 
cases, about 80%, develop recurrence within the first 2 years post resection which 
emphasizes the need for more frequent follow-up during this period. 
(6,7)
  
Based on the latest available Malaysian NCR data, 70.8% of colorectal cancer cases between 
2008 and 2013 were treated by surgical resection whilst 88.4% of patients diagnosed with 
stage III colorectal cancer were treated surgically. Of these patients who underwent surgery, 
about 16% underwent laparoscopic colectomy.  
It has become common knowledge that laparoscopic surgeries have produced better outcomes 
such as reduced post-operative pain, faster return of bowel function and subsequently, 
reduced hospital stays and faster return to work. This has made the laparoscopic approach 
more favorable compared to open. 
(8)
 
Here in Hospital Universiti Sains Malaysia (HUSM), one of the major teaching hospitals in 
Malaysia, laparoscopic surgeries have been in place since the mid-1990s but laparoscopic 
colectomy for colorectal carcinoma has been used as the choice technique only recently.   
Being a technically-demanding procedure, the laparoscopic approach for resection of 
colorectal malignancies poses a steep learning curve for the novice surgical team. 
(9)
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Consequently, in this process of gaining new skills, the short and long-term outcomes may be 
greatly influenced. 
Currently, there is no existing data on our progress in terms of the oncologic outcome of the 
cases of laparoscopically resected colorectal cancers. Possibly, more information at hand may 
serve as an encouragement to choose the laparoscopic approach to resection of colorectal 
carcinomas. And, perhaps, it can help us to identify any short-comings in our perioperative 
management and post-operative follow-up.  
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Objectives 
 
Primary objective  
To determine the proportion cases of with recurrence within 2 years post-surgery amongst 
those who had undergone laparoscopic resection of colorectal carcinomas in HUSM. 
Secondary objectives  
To describe factors that may contribute to the risk of recurrence, specifically:  
- Patient factors (age and gender, co-morbid diseases) 
- Disease factors (pre- and post-operative staging, tumour site and serum 
Carcinoembryonic Antigen (CEA) levels) 
- Histopathologic factors (TNM stage, histologic type and differentiation of the tumour, 
involvement of resection margin)  
- Presence of neoadjuvant or adjuvant therapy  
- Time lapse between surgery and commencement of neoadjuvant and/or adjuvant 
therapy 
 
Research Questions 
What is the 2-year recurrence rate of colorectal carcinoma in laparoscopically resected 
colorectal carcinoma done in HUSM? 
What are the factors that may contribute towards recurrence (particularly in terms of patient 
demographics, intraoperative findings and histopathological findings, duration of which 
adjuvant therapy is given)? 
 
Research Hypothesis 
H0: The recurrence rate of laparoscopically resected CRC done in HUSM is comparable to 
international standards. 
HA: The recurrence rate of laparoscopically resected CRC done in HUSM is not comparable 
international standards. 
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Literature review 
 
As  acknowledged earlier, surgical resection is considered the primary treatment modality in 
most cases and curative results can be achieved with appropriate adjuvant therapy. Keeping 
in mind the need for an oncologically-sound resection, the surgeon‘s goals would include 
complete excision of the primary tumour, its major vascular pedicle and lymphatic drainage 
basin of the affected colonic segment.
 (8)
 Resection can be done either by the ―contemporary‖ 
laparoscopic or the ―conventional‖ open approach. 
In the past decades, laparoscopic colectomy for resection of colorectal malignancies has been 
gaining its popularity though at a slow pace. There have been concerns regarding the 
oncologic outcomes of laparoscopically-resected colorectal malignancies as previously 
highlighted in a report of the forth port-site recurrence post laparoscopic colectomy by 
Cirrocco et al. 
(10)
 The latter had even concluded that ―abdominal wall cancer recurrence is 
enhanced by the laparoscopic approach to colorectal cancer‖ and shunned the method, 
suggesting that it only be performed in controlled, clinical studies. 
Thus, the ‗dark age‘ of laparoscopic colectomy for malignancy ensued until a number of 
large, prospective, randomized controlled studies such as the Barcelona, MRC-CLASSIC, 
COLOR and COST trials compared open to laparoscopic approach and addressed the major 
concern of oncologic safety.  
The Barcelona trial involved 208 randomly selected patients who fit the inclusion criteria of a 
single tumour at least 15cm from the anal verge and studied their cancer-related survival over 
a 5-year period. They found that laparoscopic resection was superior in stage III colon cancer. 
(11)
 
A 48-instituition-strong multicentric randomized control study performed by the COST study 
group recruited a massive sample of 1735 patients with the primary study objective of ―time 
to tumour recurrence‖. What they found was that the recurrent rates in laparoscopic-assisted 
colectomy and open colectomy were comparable and thus, an acceptable alternative to open 
surgery. 
(12)
  Based on this data, it was also studied that laparoscopic colectomy was not 
inferior to open surgery.
 (13)
 
Consolidating all the above trials in a meta-analysis was a refreshing effort by Transatlantic 
Laparoscopically Assisted vs Open Colectomy Trials Study Group who aimed to ―enhance‖ 
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the surgeon‘s power to choose between laparoscopic or open techniques. They concluded that 
laparoscopic colectomy was oncologically safe.
 (14)
 
Evidently, as noted by the COLOR study group in 2005, a higher volume of cases has been 
shown to have a positive impact on the short-term results of laparoscopic colectomy for 
colorectal carcinoma. 
(15)
 A self-audit done by the Royal Brisbane Hospital in Australia 
showed that amongst the 181 patients who underwent laparoscopic resection for colorectal 
cancer in their hospital, the procedure produces acceptable intermediate to long-term 
oncologic outcomes and a low long-term complication rate in selected patients. 
(16)
   
Perhaps owing to the steep learning curve and advanced skills required, not many surgeons 
choose or are able to perform laparoscopic resection in Malaysia. This is reflected in 
Malaysian local census which found that only about 16% of colorectal carcinoma cases 
underwent laparoscopic resection. To date, there is no existing local data on the oncologic 
outcomes of laparoscopically resected colorectal cancers. Keeping in mind that majority of 
cases recur within the first 2 years of resection, it seems logical to look into the recurrence 
rates within this period when evaluating our progress at the early stage of our learning curve. 
Thus, this study aims to provide better knowledge of the oncologic outcome of laparoscopic 
colectomy in HUSM and describe the factors that may contribute to higher risk for 
recurrence. 
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Methodology 
 
Study design 
This is a retrospective observational study of the patients diagnosed with colorectal cancer 
who underwent laparoscopic colectomy in HUSM from January 2007 to January 2014. 
 
Sampling 
Reference population: Colorectal cancer patients in Kelantan 
 
Source population: Colorectal cancer patients who underwent laparoscopic colectomy from 
January 2007 to January 2014 in HUSM.  
 
Sampling frame: Patients listed in the Operation Theatre Census books as having undergone 
laparoscopic colectomy for colorectal cancer in HUSM from January 2007 to January 2014. 
Only the data from patients who meet the inclusion and exclusion criteria will be used for this 
study. 
Inclusion Criteria 
1 Traceable records 
2 Underwent elective laparoscopic colectomy between 2007 to 2014 and had a post-
operative follow-up period of at least 2 years. 
3 Diagnosed with colorectal cancer  
Exclusion Criteria 
1 Missed follow-up 
2 Presence of different concurrent pathology 
 
Sampling method:  No sampling method applied 
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Sample size determination  
The sample size determination for this study was obtained using Power and Sample Size 
Calculation (PS) Software. The significant level was set at (α) 0.05 and the power study (1- 
β) was 80%. The sample size estimation will be based on survival analysis. The ratio of 
control to cases (m) and medium survival time on control (m1) was obtained from experts. 
The accrual time (A) for this study will be seven years (84 months) and there will be about 24 
months (F) additional follower up after the recruitment. The detectable hazard ratio of the 
control relative to experimental group (R) is determined by researcher and expert opinion. 
Additional 10% sample size (n) required for considering estimated 10% missing data or loss 
to follow up.  
Summarize information for sample size calculation using Power and Sample Size (PS)  
software; 
(α)       : Significant level = 0.05 
(1- β) : Power = 0.8 
(R)       : Hazard ratio (relative risk) of the control treatment relative to experimental 
treatment was determine by clinical expert = 3 
(m1)     : Medium retention time on control treatment was obtained from literature = 33 
months 
(m)       :  Ratio of control to experimental patients = 1  
(A)        : The accrual time during which subject were recruited = 84 months 
(F)         : Additional follow-up after end of recruitment = 24 months 
(n)        : Sample size determination by PS Software (Considering estimated 10% for 
missing data/loss to follow up (additional 10% was added)) 
 
Based on result of sample size calculation from Power and Sample Size Calculation (PS) 
Software, the required sample size will be 60 subject after adding 10% possible missing data 
or loss to follow up. 
 
Data collection 
Data collection will be recorded in a data collection form (Appendix 1). The following 
information will be recorded: patients‘ demographics, Serum CEA before surgery, pre and 
post-operative diagnosis and stage, histopathological report of resected specimen, time 
interval between surgery and commencement of adjuvant therapy and presence with evidence 
of recurrence.  
 
Intended statistical analysis 
Data collected will be keyed into SPSS version 23. Determination of recurrence rate, Kaplan-
Meir analysis will be used and possible risk factors for recurrence will be analysed by cox 
regression analysis.  
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Study Flow Chart  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of patients who underwent Laparoscopic colectomy between 
January 2007 to January 2014 obtained from OT census book 
 
 
Recruitment of patient who fulfill inclusion and exclusion 
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Review of medical records of patients recruited in the 
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Data from medical records entered in Data 
collection form 
 
 Data collection and statistical analysis 
 
 Report and manuscript write-up 
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Appendix 1 
Data Collection Form 
 
Patient’s Demographics 
Age At 
diagnosis 
 At Surgery  
Gender Male  Female 
Race Malay Chinese Indian Others 
Co 
morbidities 
Diabetes Hypertension Ischaemic heart disease End-stage renal failure 
Disease-Related 
Pre-
operative 
Diagnosis  Stage  
Post-
operative 
Diagnosis  Stage  
Site of 
tumour 
 Presence of synchronous tumour  
Serum CEA Pre-
operative 
 Post-
operative 
 
Histopathological Features 
TNM Stage T N M Final TNM stage:  
 
Histologic Type Adenocarcinoma Others Not specified 
Tumour 
differentiation 
Well Moderate Poor Not specified 
Number of lymph 
nodes 
 
Lymphovascular 
invasion 
Yes No 
Perineural invasion Yes No 
Tumour margin Proximal: 
involved/ not involved 
Distal: 
Involved/ not involved 
Circumferential 
(rectum/anorectum): 
involved/ not involved 
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Treatment given 
Neoadjuvant therapy 
given 
Yes No 
Type of surgery 
performed 
(laparoscopically) 
Anterior 
resection   
Right 
hemicolectomy 
Left 
hemicolectomy 
Abdominoperineal 
resection 
Others (please 
specify): 
Adjuvant therapy 
given 
Yes: 
Chemotherapy/ Radiotherapy/ Both 
No: 
Time interval between 
completion of 
neoadjuvant therapy 
and surgery 
 
Time interval between 
surgery and 
commencement of 
adjuvant therapy 
 
Follow-up details (during first 2 years only) 
Post-operative follow-
up interval (in months) 
 
Disease recurrence Yes No 
Site of recurrence: 
Post-operative 
mortality within 2 
years 
Yes No 
Disease-related morbidity:  
Yes 
No 
Unknown 
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